RxSight, Inc. (RXST) stock
Close on Nov 11, 2026Market cap $219.61MP/E –Yield –
RxSight, Inc. saw revenue fall 13.2% to $127.58M over the twelve months to Jun 30, 2026. Free cash flow was -$27.17M. At the latest close the market valued the company at $219.61M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $219.61M
- P/E ratio
- –
- Price to sales
- 1.72
- Price to book
- 0.83
- Dividend yield
- –
- Free cash flow yield
- -12.37%
Fundamentals
- Revenue
- $127.58M
- Net income
- -$46.95M
- EPS, diluted
- -$1.13
- Free cash flow
- -$27.17M
- Book value per share
- $6.35
- Diluted shares
- 41M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $4.90
- Open
- $4.87
- Day's range
- $4.84 – $5.29
- Volume
- 808,160
- Average volume (20 days)
- 909,746
- Index membership
- Russell 2000 (since Sep 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 1.11
- 52-week range
- $4.11 – $13.22
- RSI (14 days)
- 58.4
- Volatility (1 year)
- 62.9%
- Relative volume
- 0.91×
- WACC
- 10.4%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RXST | S&P 500 | Difference | RXST per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.8% | -2.4% | +12.2 pts | ||
| 3 months | -25.0% | -1.2% | −23.8 pts | ||
| Year to date | -49.3% | +12.3% | −61.6 pts | ||
| 1 year | -48.4% | +12.4% | −60.8 pts | ||
| 3 years | -79.1% | +78.8% | −157.9 pts | -40.7% | +21.4% |
| 5 years | -58.2% | +75.2% | −133.4 pts | -16.0% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases RxSight filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About RxSight
Ophthalmic Goods
RxSight, Inc. is a commercial-stage medical technology company that provides customized vision solutions to patients following cataract surgery. The company develops, manufactures, and markets the proprietary RxSight Light Adjustable Lens system, an adjustable intraocular lens technology. This system includes the Light Adjustable Lens, the Light Delivery Device, and associated accessories. The technology allows ophthalmic surgeons to modify lens power and astigmatic correction non-invasively through ultraviolet light treatments after surgical implantation, rather than relying exclusively on preoperative estimates. Its primary customers are ophthalmologists and cataract surgeons, as well as ophthalmic practices and ambulatory surgery centers.
Company profile, executives and historyRxSight stock: common questions
What is RxSight's stock price?
RXST closed at $5.28 on Nov 11, 2026, up 7.76% on the day. Over the past 52 weeks it traded between $4.11 and $13.22.
What is RxSight's market cap?
RxSight was worth $219.61M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RXST's P/E ratio?
RxSight lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.13), so it has no meaningful P/E ratio.
How much revenue does RxSight make?
RxSight reported revenue of $127.58M for the twelve months to Jun 30, 2026, down 13.2% from a year earlier.
Does RxSight pay a dividend?
No. RxSight has not paid a cash dividend over the last twelve months.
When does RxSight report earnings next?
RxSight is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RXST stock performed over the past year?
Including dividends, RXST returned -48.4% over the past year, against +12.4% for the S&P 500.
How many RXST shares are sold short?
4M shares were sold short at the latest FINRA report, 9.23% of the float, or 6.1 days of average trading volume.
Who are RxSight's competitors?
Companies most similar to RxSight by business, industry and size include STAA, LNSR, SGHT, IRIX, SMTI.
See a number that looks wrong?